Table 2 Disease characteristics and therapy at baseline and during follow-up.

From: Sociodemographic factors and biologic therapy exposure impacting health-related quality of life in psoriatic arthritis - findings from a nationwide registry Reuma.pt

Characteristics

T0

n = 342

T1

n = 309

T2

n = 168

Patient’s Global Assessment (mean ± sd)

41.6 (28.8)

31.9 (26.3)

30.4 (25.4)

Physician’s Global Assessment (mean ± sd)

24.1 (21.9)

13.5 (14.6)

11.6 (13.2)

Pain VAS (0-100) (mean ± sd)

41.0 (29.2)

31.9 (26.3)

30.4 (25.4)

Number swollen joints (mean ± sd)

1.9 (3.3)

0.8 (1.7)

0.6 (2.0)

Number tender joints (mean ± sd)

5.6 (9.0)

2.6 (5.8)

2.0 (5.4)

Number dactylitis (mean ± sd)

62 (24.9)

55 (24.7)

25 (19.5)

Psoriasis n, %

157 (63.1)

140 (62.8)

76 (59.4)

CRP mg/L (mean ± sd)

9.5 (18.5)

5.3 (11.0)

6.7 (14.2)

DAS28 4v (mean ± sd)

3.2 (1.6)

2.5 (1.2)

2.6 (1.3)

DAPSA (mean ± sd)

24.7 (26.1)

14.6 (15.8)

14.8 (19.1)

DAPSA n, %

   

Remission

42 (12.2)

65 (24.3)

36 (24.7)

Low Disease activity

90 (32.4)

98 (36.7)

59 (40.4)

Moderate Disease activity

73 (26.7)

75 (28.1)

36 (24.7)

High disease activity

88 (28.7)

29 (10.9)

15 (10.3)

ASDAS (mean ± sd)

2.8 (1.2)

2.2 (1.0)

2.1 (1.0)

ASDAS n, %

   

Inactive Disease

20 (13.3)

27 (22.9)

18 (27.7)

Low Disease activity

29 (19.2)

31 (26.3)

18 (27.7)

High Disease activity

60 (39.7)

46 (39.0)

26 (40.0)

Very High Disease activity

42 (27.8)

14 (11.9)

3 (4.6)

Corticosteroids n, %

103 (30.1)

86 (27.8)

36 (21.4)

NSAIDs n, %

188 (55.0)

163 (52.8)

94 (56.0)

csDMARDs n, %

225 (65.8)

198 (64.08)

133 (67.2)

b/tsDMARDs n, %

236 (69.0)

236 (75.7)

138 (81.6)

Adalimumab

76 (32.2)

78 (33.1)

42 (30.4)

Certolizumab

4 (1.7)

7 (3.0)

3 (2.2)

Etanercept

87 (36.9)

83 (35.2)

43 (31.2)

Golimumab

36 (15.3)

31 (13.1)

23 (16.7)

Infliximab

16 (6.8)

14 (5.9)

12 (8.7)

Secukinumab

14 (5.9)

17 (7.2)

10 (7.2)

Tocilizumab

23 (0.9)

3 (1.3)

1 (0.7)

Ustekinumab

1 (0.4)

1 (0.4)

2 (1.4)

Tofacitinib

-

2 (0.8)

1 (0.7)

b/tsDMARDS at baseline n, %

   

Never

78 (24.2)

-

-

In the past

6 (1.9)

-

-

1

195 (60.6)

-

-

2

31 (9.6)

-

-

3

10 (3.1)

-

-

4 or more

2 (0.6)

-

-

b/tsDMARDS therapy changes n, %

   

Constant (same biologic)

-

187 (81.7)

97 (77.0)

Cycling

-

21 (9.2)

16 (12.7)

Switch

-

21 (9.2)

13 (10.3)

  1. T0 – baseline evalution; T1–1-year evaluation; T2–3-year evaluation; VAS – visual analog scale; CRP – C-Reactive Protein; DAS28 – Disease Activity Score 28 joint count; DAPSA - Disease Activity Index for Psoriatic Arthritis; ASDAS - Ankylosing Spondylitis Disease Activity Score; NSAIDs - non-steroidal anti-inflammatory drugs; csDMARDs - conventional synthetic Disease-Modifying Anti-Rheumatic Drug; b/tsDMARDs – biologic or target synthetic Disease-Modifying Anti-Rheumatic Drugs.
Back to article page